Endo Acquires Patent for Oxymorphone Hydrochloride from Johnson Matthey

Endo Pharmaceuticals (Chadds Ford, PA) says it has acquired U.S. patent for oxymorphone hydrochloride, the key active pharmaceutical ingredient (API) in all formulations of paint management product Opana, from Johnson Matthey (London). By acquiring Johnson Matthey's patent to the oxymorphone ingredient, which will be listed in the U.S. Food and Drug Administration's (FDA) orange book, Endo will enjoy additional patent protection for its Opana franchise, now through 2029, Endo says. “This patent not only covers our newly designed to be crush resistant Opana...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers